<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Characteristics of the autosomal dominant spinocerebellar ataxias</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Characteristics of the autosomal dominant spinocerebellar ataxias</h1>
<div class="graphic"><div class="figure"><div class="ttl">Characteristics of the autosomal dominant spinocerebellar ataxias</div><div class="cntnt"><table cellspacing="0"><colgroup width="12%"></colgroup> <colgroup width="33%"></colgroup> <colgroup width="12%"></colgroup> <colgroup width="33%"></colgroup> <colgroup width="10%"></colgroup> <tbody> <tr> <td class="subtitle1">Disorder</td> <td class="subtitle1">Distinguishing features</td> <td class="subtitle1" colspan="2">Gene locus and protein</td> <td class="subtitle1">OMIM#</td> </tr> <tr> <td>SCA1</td> <td>Pyramidal signs, peripheral neuropathy, ophthalmoplegia</td> <td><em>ATXN1</em></td> <td>Ataxin 1; CAG repeat</td> <td><a href="https://omim.org/entry/601556?search=ATXN1&amp;highlight=atxn1" target="_blank">601556</a></td> </tr> <tr> <td>SCA2</td> <td>Slow saccades; less often parkinsonism, myoclonus, areflexia, dementia</td> <td><em>ATXN2</em></td> <td>Ataxin 2; CAG repeat</td> <td><a href="https://omim.org/entry/601517?search=ATXN2&amp;highlight=atxn2" target="_blank">601517</a></td> </tr> <tr> <td>SCA3 (MJD)</td> <td>Slow saccades, persistent stare, extrapyramidal signs, peripheral neuropathy</td> <td><em>ATXN3</em></td> <td>Ataxin 3 (MJD1); CAG repeat</td> <td><a href="https://omim.org/entry/607047?search=ATXN3&amp;highlight=atxn3" target="_blank">607047</a></td> </tr> <tr> <td>SCA4</td> <td>Sensory axonal neuropathy</td> <td>16q22.1</td> <td> </td> <td><a href="https://omim.org/entry/600223?search=SCA4&amp;highlight=sca4" target="_blank">600223</a></td> </tr> <tr> <td>SCA5</td> <td>Early onset but slow progression</td> <td><em>SPTBN2</em></td> <td>Spectrin beta, nonerythrocytic 2</td> <td><a href="https://omim.org/entry/604985?search=SPTBN2&amp;highlight=sptbn2" target="_blank">604985</a></td> </tr> <tr> <td>SCA6</td> <td>May have very late onset, mild, may lack family history, nystagmus</td> <td><em>CACNA1A</em></td> <td>Calcium voltage-gated channel subunit alpha1 A; CAG repeat</td> <td><a href="https://omim.org/entry/601011?search=CACNA1A&amp;highlight=cacna1a" target="_blank">601011</a></td> </tr> <tr> <td>SCA7</td> <td>Ataxia, retinal degeneration</td> <td><em>ATXN7</em></td> <td>Ataxin 7; CAG repeat</td> <td><a href="https://omim.org/entry/607640?search=ATXN7&amp;highlight=atxn7" target="_blank">607640</a></td> </tr> <tr> <td>SCA8</td> <td>Mild disease</td> <td><em>ATXN8OS</em></td> <td>ATXN8 opposite strand IncRNA; CTG*CAG repeat</td> <td><a href="https://omim.org/entry/603680?search=SCA8&amp;highlight=sca8" target="_blank">603680</a></td> </tr> <tr> <td>SCA9</td> <td>Not assigned</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td>SCA10</td> <td>Generalized or focal with impaired awareness seizures</td> <td><em>ATXN10</em></td> <td>Ataxin 10; ATTCT repeat</td> <td><a href="https://omim.org/entry/611150?search=ATXN10&amp;highlight=atxn10" target="_blank">611150</a></td> </tr> <tr> <td>SCA11</td> <td>Mild disease</td> <td><em>TTBK2</em></td> <td>Tau tubulin kinase 2</td> <td><a href="https://omim.org/entry/611695?search=TTBK2&amp;highlight=ttbk2" target="_blank">611695</a></td> </tr> <tr> <td>SCA12</td> <td>Tremor, dementia</td> <td><em>PPP2R2B</em></td> <td>Protein phosphatase 2 regulatory subunit Bbeta; CAG repeat in 5' region</td> <td><a href="https://omim.org/entry/604325?search=PPP2R2B&amp;highlight=ppp2r2b" target="_blank">604325</a></td> </tr> <tr> <td>SCA13</td> <td>Intellectual disability</td> <td><em>KCNC3</em></td> <td>Potassium voltage-gated channel subfamily C member 3</td> <td><a href="https://omim.org/entry/176264?search=KCNC3&amp;highlight=kcnc3" target="_blank">176264</a></td> </tr> <tr> <td>SCA14</td> <td>Intermittent myoclonus with early-onset disease</td> <td><em>PRKCG</em></td> <td>Protein kinase C gamma</td> <td><a href="https://omim.org/entry/176980?search=PRKCG&amp;highlight=prkcg" target="_blank">176980</a></td> </tr> <tr> <td>SCA15/16</td> <td>Slowly progressive; sometimes with myoclonus, dystonia</td> <td><em>ITPR1</em></td> <td>Inositol 1,4,5-triphosphate receptor type 1</td> <td><a href="https://omim.org/entry/147265?search=ITPR1&amp;highlight=itpr1" target="_blank">147265</a></td> </tr> <tr> <td>SCA17</td> <td>Gait ataxia, dementia; can present with predominant chorea</td> <td><em>TBP</em></td> <td>TATA-box binding protein; CAG repeat</td> <td><a href="https://omim.org/entry/600075?search=TBP&amp;highlight=tbp" target="_blank">600075</a></td> </tr> <tr> <td>SCA18</td> <td>Pyramidal signs, weakness, sensory axonal neuropathy</td> <td><span class="nowrap_whitespace">7q22-q32</span></td> <td> </td> <td><a href="https://omim.org/entry/607458?search=SCA18&amp;highlight=sca18" target="_blank">607458</a></td> </tr> <tr> <td>SCA19/22</td> <td>Predominantly cerebellar syndrome, sometimes with cognitive impairment, myoclonus, hand tremor, neuropathy</td> <td><em>KCND3</em></td> <td>Potassium voltage-gated channel subfamily D member 3</td> <td><a href="https://omim.org/entry/605411?search=KCND3&amp;highlight=kcnd3" target="_blank">605411</a></td> </tr> <tr> <td>SCA20</td> <td>Palatal tremor and dysphonia</td> <td>11q12</td> <td>Contiguous gene duplication syndrome</td> <td><a href="https://omim.org/entry/608687?search=SCA20&amp;highlight=sca20" target="_blank">608687</a></td> </tr> <tr> <td>SCA21</td> <td>Mild to severe cognitive impairment</td> <td><em>TMEM240</em></td> <td>Transmembrane protein 240</td> <td><a href="https://omim.org/entry/616101?search=TMEM240&amp;highlight=tmem240" target="_blank">616101</a></td> </tr> <tr> <td>SCA23</td> <td>Distal sensory deficits</td> <td><em>PDYN</em></td> <td>Prodynorphin</td> <td><a href="https://omim.org/entry/131340?search=PDYN&amp;highlight=pdyn" target="_blank">131340</a></td> </tr> <tr> <td>SCA24</td> <td>Recessive inheritance; redesignated as SCAR4</td> <td><em>VPS13D</em></td> <td>Vacuolar protein sorting 13 <span class="nowrap_whitespace">homolog D</span></td> <td><a href="https://omim.org/entry/607317?search=SCA24&amp;highlight=sca24" target="_blank">607317</a></td> </tr> <tr> <td>SCA25</td> <td>Sensory neuropathy, facial tics, gastrointestinal symptoms</td> <td><em>PNPT1</em></td> <td>Polyribonucleotide nucleotidyltransferase 1</td> <td><a href="https://omim.org/entry/608703?search=SCA25&amp;highlight=sca25" target="_blank">608703</a></td> </tr> <tr> <td>SCA26</td> <td>Pure cerebellar ataxia</td> <td><em>EEF2</em></td> <td>Eukaryotic translation elongation factor 2</td> <td><a href="https://omim.org/entry/130610?search=EEF2&amp;highlight=eef2" target="_blank">130610</a></td> </tr> <tr> <td>SCA27A</td> <td>Cognitive impairment; early-onset hand tremor, orofacial dyskinesia</td> <td><em>FGF14</em></td> <td>Fibroblast growth factor 14</td> <td><a href="https://omim.org/entry/601515?search=FGF14&amp;highlight=fgf14" target="_blank">601515</a></td> </tr> <tr> <td>SCA27B</td> <td>Late-onset cerebellar ataxia</td> <td><em>FGF14</em></td> <td>Fibroblast growth factor 14, intronic GAA repeat expansion</td> <td><a href="https://omim.org/entry/601515?search=FGF14&amp;highlight=fgf14" target="_blank">601515</a></td> </tr> <tr> <td>SCA28</td> <td>Ophthalmoparesis and ptosis</td> <td><em>AFG3L2</em></td> <td>AFG3 like matrix AAA peptidase subunit 2</td> <td><a href="https://omim.org/entry/604581?search=afg3l2&amp;highlight=afg3l2" target="_blank">604581</a></td> </tr> <tr> <td>SCA29</td> <td>Early-onset, nonprogressive ataxia; may be an allelic variant of SCA15</td> <td>3p26</td> <td> </td> <td><a href="https://omim.org/entry/117360?search=SCA29&amp;highlight=sca29" target="_blank">117360</a></td> </tr> <tr> <td>SCA30</td> <td>Slowly progressive, relatively pure ataxia</td> <td><span class="nowrap_whitespace">4q34.3-q35.1</span></td> <td> </td> <td><a href="https://omim.org/entry/613371?search=SCA30&amp;highlight=sca30" target="_blank">613371</a></td> </tr> <tr> <td>SCA31</td> <td>Decreased muscle tone, hearing loss, vertigo</td> <td><em>BEAN1</em></td> <td>Brain expressed associated with NEDD4 1; (TGGAA)n repeat</td> <td><a href="https://omim.org/entry/612051?search=BEAN1&amp;highlight=bean1" target="_blank">612051</a></td> </tr> <tr> <td>SCA32</td> <td>Cognitive impairment, affected males with azoospermia and testicular atrophy</td> <td><span class="nowrap_whitespace">7q32-q33</span></td> <td> </td> <td><a href="https://omim.org/entry/613909?search=Spinocerebellar%20ataxia%2032&amp;highlight=%28atactic%7Cataxia%7Cataxic%7Cataxy%29%2032%20spinocerebellar" target="_blank">613909</a></td> </tr> <tr> <td>SCA33</td> <td>Not assigned</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td>SCA34</td> <td>Skin lesions consisting of papulosquamous erythematous ichthyosiform plaques</td> <td><em>ELOVL4</em></td> <td>ELOVL fatty acid elongase 4</td> <td><a href="https://omim.org/entry/605512?search=ELOVL4&amp;highlight=elovl4" target="_blank">605512</a></td> </tr> <tr> <td>SCA35</td> <td>Late onset, slowly progressive gait and limb ataxia; cervical dystonia</td> <td><em>TGM6</em></td> <td>Transglutaminase 6</td> <td><a href="https://omim.org/entry/613900?search=TGM6&amp;highlight=tgm6" target="_blank">613900</a></td> </tr> <tr> <td>SCA36</td> <td>Late onset, truncal ataxia, dysarthria, variable motor neuron disease and sensorineural hearing loss</td> <td><em>NOP56</em></td> <td>NOP56 ribonucleoprotein; GGCCTG repeat</td> <td><a href="https://omim.org/entry/614154?search=NOP56&amp;highlight=nop56" target="_blank">614154</a></td> </tr> <tr> <td>SCA37</td> <td>Late onset, falls, dysarthria, clumsiness, abnormal vertical eye movements</td> <td><em>DAB1</em></td> <td>DAB adaptor protein 1</td> <td><a href="https://omim.org/entry/603448?search=DAB1&amp;highlight=dab1" target="_blank">603448</a></td> </tr> <tr> <td>SCA38</td> <td>Slowly progressive relatively pure cerebellar phenotype; neuropathy</td> <td><em>ELOVL5</em></td> <td>ELOVL fatty acid elongase 5</td> <td><a href="https://omim.org/entry/611805?search=ELOVL5&amp;highlight=elovl5" target="_blank">611805</a></td> </tr> <tr> <td>SCA39</td> <td>Not assigned</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td>SCA40</td> <td>Hyperreflexia and spasticity, tremor, parkinsonism</td> <td><em>CCDC88C</em></td> <td>Coiled-coil domain-containing 88C</td> <td><a href="https://omim.org/entry/611204?search=CCDC88C&amp;highlight=ccdc88c" target="_blank">611204</a></td> </tr> <tr> <td>SCA41</td> <td>Gait ataxia</td> <td><em>TRPC3</em></td> <td>Transient receptor potential cation channel subfamily C member 3</td> <td><a href="https://omim.org/entry/602345?search=TRPC3&amp;highlight=trpc3" target="_blank">602345</a></td> </tr> <tr> <td>SCA42</td> <td>Early motor delay, hypotonia, speech delay, severe intellectual disability, ataxia, facial myokymia</td> <td><em>CACNA1G</em></td> <td>Calcium voltage-gated channel subunit alpha 1G</td> <td><a href="https://omim.org/entry/604065?search=CACNA1G&amp;highlight=cacna1g" target="_blank">604065</a></td> </tr> <tr> <td>SCA43</td> <td>Gait ataxia, neuropathy, hyporeflexia, tremor</td> <td><em>MME</em></td> <td>Membrane metalloendopeptidase</td> <td><a href="https://omim.org/entry/120520?search=SCA43&amp;highlight=sca43" target="_blank">120520</a></td> </tr> <tr> <td>SCA44</td> <td>Ataxia, dysarthria, dysmetria, dysphagia</td> <td><em>GRM1</em></td> <td>Glutamate metabotropic receptor 1</td> <td><a href="https://omim.org/entry/604473?search=GRM1&amp;highlight=grm1" target="_blank">604473</a></td> </tr> <tr> <td>SCA45</td> <td>Limb and gait ataxia, downbeat nystagmus, dysarthria</td> <td><em>FAT2</em></td> <td>FAT atypical cadherin 2</td> <td><a href="https://omim.org/entry/604269?search=FAT2&amp;highlight=fat2" target="_blank">604269</a></td> </tr> <tr> <td>SCA46</td> <td>Neuropathy and sensory ataxia affecting lower limbs more than upper limbs, cerebellar atrophy</td> <td><em>PLD3</em></td> <td>Phospholipase D family member 3</td> <td><a href="https://omim.org/entry/615698?search=PLD3&amp;highlight=pld3" target="_blank">615698</a></td> </tr> <tr> <td>SCA47</td> <td>Early-onset developmental disability, ataxia, chorea, seizure; later-onset ataxia, dysarthria, dysmetria</td> <td><em>PUM1</em></td> <td>Pumilio RNA binding family <span class="nowrap_whitespace">member 1</span></td> <td><a href="https://omim.org/entry/607204?search=PUM1&amp;highlight=pum1" target="_blank">607204</a></td> </tr> <tr> <td>SCA48</td> <td>Gait ataxia, cognitive dysfunction in adulthood</td> <td><em>STUB1</em></td> <td>STIP1 homology and U-box containing protein 1</td> <td><a href="https://omim.org/entry/607207?search=STUB1&amp;highlight=stub1" target="_blank">607207</a></td> </tr> <tr> <td><span class="nowrap_whitespace">ATX-ATN1</span> (DRPLA)</td> <td>Chorea, seizures, myoclonus, dementia</td> <td><em>ATN1</em></td> <td>Atrophin 1; CAG repeat</td> <td><a href="https://omim.org/entry/607462?search=ATN1&amp;highlight=atn1" target="_blank">607462</a></td> </tr> <tr> <td><span class="nowrap_whitespace">ATX-DAB1</span></td> <td>Adult-onset, slowly progressive</td> <td><em>DAB1</em></td> <td>DAB adaptor protein 1</td> <td><a href="https://omim.org/entry/615945?search=615945&amp;highlight=615945" target="_blank">615945</a></td> </tr> <tr> <td><span class="nowrap_whitespace">ATX-DNMT1</span></td> <td>Sensorineural deafness, narcolepsy, dementia</td> <td><em>DNMT1</em></td> <td>DNA methyltransferase 1</td> <td><a href="https://omim.org/entry/126375?search=DNMT1&amp;highlight=dnmt1" target="_blank">126375</a></td> </tr> <tr> <td><span class="nowrap_whitespace">ATX-EBF3</span></td> <td>Hypotonia, ataxia, and delayed development syndrome (HADDS)</td> <td><em>EBF3</em></td> <td>EBF transcription factor 3</td> <td><a href="https://omim.org/entry/617330?search=617330&amp;highlight=617330" target="_blank">617330</a></td> </tr> <tr> <td><span class="nowrap_whitespace">ATX-LMNB1</span></td> <td>Autosomal dominant, adult-onset demyelinating <span class="nowrap_whitespace">leukodystrophy (ADLD)</span></td> <td><em>LMNB1</em></td> <td>Lamin B1</td> <td><a href="https://omim.org/entry/169500?search=169500&amp;highlight=169500" target="_blank">169500</a></td> </tr> <tr> <td><span class="nowrap_whitespace">ATX-SAMD9L</span></td> <td>Ataxia-pancytopenia <span class="nowrap_whitespace">syndrome (ATXPC)</span></td> <td><em>SAMD9L</em></td> <td>Sterile alpha motif domain containing 9 like</td> <td><a href="https://omim.org/entry/159550?search=159550&amp;highlight=159550" target="_blank">159550</a></td> </tr> <tr> <td><span class="nowrap_whitespace">ATX-SNAP25b</span></td> <td>Early-onset myasthenia, developmental delay, intellectual disability, seizures, craniofacial dysmorphism, rarely tremor</td> <td><em>SNAP25b</em></td> <td>Synaptosome associated protein 25b</td> <td><a href="https://omim.org/entry/616330?search=616330&amp;highlight=616330" target="_blank">616330</a></td> </tr> <tr> <td><span class="nowrap_whitespace">ATX-TUBB2A</span></td> <td>Spasticity, developmental delay, seizures, distal amyotrophy, rarely optic atrophy</td> <td><em>TUBB2A</em></td> <td>Tubulin beta 2A class IIa</td> <td><a href="https://omim.org/entry/615101?search=TUBB2A&amp;highlight=tubb2a" target="_blank">615101</a></td> </tr> <tr> <td><span class="nowrap_whitespace">ATX/HSP-VAMP1</span> (SPAX1)</td> <td>Spastic ataxia, supranuclear upward gaze palsy</td> <td><em>VAMP1</em></td> <td>Vesicle associated membrane protein 1</td> <td><a href="https://omim.org/entry/108600#:~:text=Spastic%20ataxia%2D1%20(SPAX1)%20is%20an%20autosomal%20dominant%20form,sense%20in%20the%20lower%20limbs." target="_blank">108600</a></td> </tr> </tbody></table></div><div class="graphic_footnotes">SCA: spinocerebellar ataxia; MJD: Machado-Joseph disease; DRPLA: dentatorubral pallidoluysian atrophy; ATX: ataxia; HSP: hereditary spastic paraplegia; SPAX1: spastic ataxia 1.</div><div class="graphic_reference">Data from: <a href="https://www.ncbi.nlm.nih.gov/omim" target="_blank">Online Mendelian Inheritance in Man</a> and <a href="https://neuromuscular.wustl.edu/ataxia/domatax.html" target="_blank">Neuromuscular Disease Center, Washington University</a> and <a href="https://www.movementdisorders.org/MDS/About/Committees--Other-Groups/Study-Groups/Genetic-Nomenclature-in-Movement-Disorders.htm" target="_blank">International Parkinson and Movement Disorder Society</a>.</div><div id="graphicVersion">Graphic 74269 Version 15.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
